Latest News Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference Oct 20 2021 Latest News Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference Sep 27 2021 Latest News Senhwa’s Pidnarulex to Combined With Pfizer’s Talazoparib in a Clinical Trial for the Treatment of Prostate Cancer Sep 22 2021 Media Coverage Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference Oct 20 2021 Media Coverage Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference Sep 27 2021 Media Coverage Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations Sep 10 2021 Publications Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 Publications Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic Dec 17 2020 Publications Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance Oct 14 2020